McKesson to Acquire Precision Medicine Group for $2.25 Billion to Boost Oncology Unit

Key Facts

1McKesson announced the acquisition of Precision Medicine Group for $2.25 billion in cash.

2The deal aims to bolster the Oncology and Multispecialty unit by integrating biomarker-driven clinical research.

In a move reflecting the strategic shift toward advanced specialized healthcare, McKesson has announced an agreement to acquire Precision Medicine Group for $2.25 billion in cash. The acquisition is designed to bolster the company’s Oncology and Multispecialty unit by integrating biomarker-driven clinical research capabilities. Through this deal, McKesson aims to accelerate oncology innovation and support biopharma companies across the entire product lifecycle, from clinical development to commercialization and patient access.

This transaction aligns with McKesson's organizational restructuring aimed at accelerating growth in high-margin areas such as biopharma services. According to market data, McKesson stock (0JZU.L) stood at $869.4 at close on August 24, 2026, having traded between a day high of $886 and a day low of $842.2. The $2.25 billion investment underscores the company's commitment to expanding its specialized healthcare network and clinical research footprint.

Traders should monitor the stock's performance relative to its recent trading range of $842.2 to $886 (as of August 24, 2026 close). While the upcoming economic calendar does not feature direct healthcare sector catalysts, broader market sentiment remains influenced by recent high-impact data, including US jobless claims and Japanese inflation rates released earlier this month.